Characterization of an orthotopic gastric cancer mouse model with lymph node and organ metastases using bioluminescence imaging Corrigendum in /10.3892/ol.2020.11860

Feng,Hai‑Yi; Zhang,Yunpeng; Liu,Hai‑Jun; Dong,Xiao; Yang,Si‑Cong; Lu,Qin; Meng,Fanping; Chen,Hong‑Zhuan; Sun,Peng; Fang,Chao

doi:10.3892/ol.2018.9313

Characterization of an orthotopic gastric cancer mouse model with lymph node and organ metastases using bioluminescence imaging

Corrigendum in: /10.3892/ol.2020.11860

Authors:
- Hai‑Yi Feng
- Yunpeng Zhang
- Hai‑Jun Liu
- Xiao Dong
- Si‑Cong Yang
- Qin Lu
- Fanping Meng
- Hong‑Zhuan Chen
- Peng Sun
- Chao Fang
View Affiliations

Affiliations: Department of General Surgery, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, P.R. China, Hongqiao International Institute of Medicine, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, P.R. China, College of Medicine, Yanbian University, Yanji, Jilin 133002, P.R. China, Department of Pharmacology and Chemical Biology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China
Published online on: August 16, 2018 https://doi.org/10.3892/ol.2018.9313
Pages: 5179-5185
Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lymph node (LN) metastasis of gastric cancer (GC) is the strongest prognostic indicator for this disease; however, the majority of the LN metastasis profiles of GC remain unknown, which notably hinders the therapeutic efficacy in clinic. In the present study, an orthotopic model of human GC was established for investigation of time‑dependent LN metastasis patterns in mice. Luciferase‑expressing NCI‑N87 human GC cells were injected into the subserosa of the gastric body, resulting in a tumor formation rate of 100%. LN metastasis at four different anatomical positions in the abdomen were characterized until week 10 after tumor cell injection using sensitive bioluminescence imaging and histopathological analyses. Skip LN metastases were observed at later stages (weeks 8‑10) of the experiment. Metastases in other major organs, including liver, spleen and lung, were also examined. Characterization of this orthotopic GC model and metastasis patterns in LNs and major organs should aid in the preclinical GC research regarding the metastatic mechanism and drug development.

View Figures

View References

1	Van Cutsem E, Sagaert X, Topal B, Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664. 2016. View Article : Google Scholar : PubMed/NCBI
2	Jeuck TL and Wittekind C: Gastric carcinoma: Stage migration by immunohistochemically detected lymph node micrometastases. Gastric Cancer. 18:100–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Songun I, Putter H, Kranenbarg EM, Sasako M and van de Velde CJ: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 11:439–449. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, et al: Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 14:1286–1312. 2016. View Article : Google Scholar : PubMed/NCBI
5	Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A and Arnold D; ESMO, ; Guidelines Committee, : Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27 Suppl 5:v38–v49. 2016. View Article : Google Scholar : PubMed/NCBI
6	Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, et al: Management of gastric cancer in Asia: Resource-stratified guidelines. Lancet Oncol. 14:e535–e547. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ajani JA, Lee J, Sano T, Janjigian YY, Fan D and Song S: Gastric adenocarcinoma. Nat Rev Dis Primers. 3:170362017. View Article : Google Scholar : PubMed/NCBI
8	Kim DH, Choi MG, Noh JH, Sohn TS, Bae JM and Kim S: Clinical significance of skip lymph node metastasis in gastric cancer patients. Eur J Surg Oncol. 41:339–345. 2015. View Article : Google Scholar : PubMed/NCBI
9	Choi YY, An JY, Guner A, Kang DR, Cho I, Kwon IG, Shin HB, Hyung WJ and Noh SH: Skip lymph node metastasis in gastric cancer: Is it skipping or skipped? Gastric Cancer. 19:206–215. 2016. View Article : Google Scholar : PubMed/NCBI
10	Qiao R, Liu C, Liu M, Hu H, Liu C, Hou Y, Wu K, Lin Y, Liang J and Gao M: Ultrasensitive in vivo detection of primary gastric tumor and lymphatic metastasis using upconversion nanoparticles. ACS Nano. 9:2120–2129. 2015. View Article : Google Scholar : PubMed/NCBI
11	Furukawa T, Fu X, Kubota T, Watanabe M, Kitajima M and Hoffman RM: Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue. Cancer Res. 53:1204–1208. 1993.PubMed/NCBI
12	Fujihara T, Sawada T, Hirakawa K, Chung YS, Yashiro M, Inoue T and Sowa M: Establishment of lymph node metastatic model for human gastric cancer in nude mice and analysis of factors associated with metastasis. Clin Exp Metastasis. 16:389–398. 1998. View Article : Google Scholar : PubMed/NCBI
13	Hackl C, Man S, Francia G, Milsom C, Xu P and Kerbel RS: Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut. 62:259–271. 2013. View Article : Google Scholar : PubMed/NCBI
14	Van den Broeck W, Derore A and Simoens P: Anatomy and nomenclature of murine lymph nodes: Descriptive study and nomenclatory standardization in BALB/cAnNCrl mice. J Immunol Methods. 312:12–19. 2006. View Article : Google Scholar : PubMed/NCBI
15	Bhargava S, Hotz B, Buhr HJ and Hotz HG: An orthotopic nude mouse model for preclinical research of gastric cardia cancer. Int J Colorectal Dis. 24:31–39. 2009. View Article : Google Scholar : PubMed/NCBI
16	Yin J, Cui Y, Li L, Ji J and Jiang WG: Overexpression of EPHB4 is associated with poor survival of patients with gastric cancer. Anticancer Res. 37:4489–4497. 2017.PubMed/NCBI
17	Belkhiri A, Dar AA, Zaika A, Kelley M and El-Rifai W: t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Res. 68:395–403. 2008. View Article : Google Scholar : PubMed/NCBI
18	Guo B, Zhao Z, Wang Z, Li Q, Wang X, Wang W, Song T and Huang C: MicroRNA-302b-3p suppresses cell proliferation through AKT pathway by targeting IGF-1R in human gastric cancer. Cellular Physiol Biochem. 42:1701–1711. 2017. View Article : Google Scholar
19	Burgermeister E, Xing X, Röcken C, Juhasz M, Chen J, Hiber M, Mair K, Shatz M, Liscovitch M, Schmid RM and Ebert MP: Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Res. 67:8519–8526. 2007. View Article : Google Scholar : PubMed/NCBI
20	Boku N: HER2-positive gastric cancer. Gastric Cancer. 17:1–12. 2014. View Article : Google Scholar : PubMed/NCBI